Ocaliva (obeticholic Acid) – New Contraindication For The Treatment Of Primary Biliary Cholangitis (pbc)

OCALIVA (obeticholic acid), a medication used to treat primary biliary cholangitis, is being recalled across Canada due to new safety information that makes it contraindicated for certain patients. The drug is no longer recommended for use in people with specific conditions or characteristics that were previously not identified as a concern. This recall affects all patients currently taking or prescribed this medication in Canada.

Product

OCALIVA (obeticholic acid)

Reason

New safety information

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2022-12-05

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/fcba822b-c1a0-43f3-9f81-dd49c38c628f